COMPASS Pathways plc Q1 FY2026 earnings call

• Clinical Development Progress

  • Positive topline data has been obtained from both Phase III trials (COMP005 and COMP006) for Comp360 psilocybin therapy in treatment-resistant depression (TRD), enrolling over 1,000 total patients across the program.
  • Comp360 demonstrated clinically meaningful, rapid onset, and extended durable efficacy that differentiates it from existing TRD treatments, with a well-tolerated safety profile.
  • Final 26-week Part B data from COMP006 is expected in early Q3 202X, which will complete the NDA submission dataset. All preclinical, toxicology, safety, and CMC data is complete to support a robust NDA.
  • The PTSD late-stage trial is underway, with a planned single pivotal trial design using the standard CAHPS5 primary endpoint; VA site participation is included and the company is already supporting VA-led combination studies for TRD/PTSD comorbid populations.

• Regulatory Milestones

  • Compass Pathways received the Commissioner's National Priority Voucher (CNPV), which enables an ultra-accelerated 1-2 month FDA review timeline after the final NDA module is submitted.
  • A rolling NDA submission plan has been agreed with the FDA, and initial modules are already being submitted.
  • The executive order on mental health has allowed accelerated engagement with the DEA to move forward on federal rescheduling of psilocybin, which is required post-approval for commercial distribution.
  • 90% of the U.S. population lives in states that have committed to rescheduling Comp360 within 30 days of federal DEA rescheduling, reducing post-approval access timelines.

• Commercial Preparedness

  • Compass remains on track to be fully launch ready by the end of 202X.
  • Psychedelic-specific CPT-3 codes for treatment monitoring reimbursement have already been secured, which enable full provider reimbursement for multi-hour treatment sessions.
  • Initial payer engagement is underway, with negotiations planned to begin once full clinical data is available. TRD accounts for 62% higher mental healthcare costs and 41% higher work-related costs than non-resistant major depressive disorder, supporting the value case for Comp360 to payers.
  • The commercial leadership team is fully built out, with collective experience launching over 50 products; the commercial team has already doubled in size in the last two months, with all core functions (compliance, distribution, payer outreach) underway.
  • Over 7,500 existing interventional psychiatry centers already prescribe Spravato (the only currently approved TRD drug), and the vast majority have been engaged by Compass; these centers are highly motivated to add Comp360 to their service offerings, with existing spare capacity that can accommodate Comp360 without major facility modifications.

No segment-level financial performance data was disclosed in this call. Management only noted that the company finished Q1 with a strong cash balance from successful financing and warrant exercises that will fund operations through launch and into 2028. No revenue or margin figures for product segments were provided, as Comp360 has not yet launched.

• Launch timeline guidance is maintained: Compass remains on track to be fully launch-ready by the end of 2024.
• The CNPV accelerates the FDA review timeline after final NDA submission (targeting 1-2 months for review) but does not change the required evidentiary basis for approval, so the submission timeline remains unchanged, with completion expected after Q3 2024 Part B data release.
• Cash guidance is maintained: current cash on hand from Q1 2024 financing and warrant exercises will fund operations well beyond launch and into 2028.
• No changes to the late-stage PTSD trial plan; it remains a single pivotal trial on track for execution, with no acceleration of trial timelines guided at this call.

• Uncertainty remains around whether the FDA will call an advisory committee (adcom) for Comp360; the decision is entirely at the FDA's discretion after reviewing the full NDA dataset, and while Compass is prepared for an adcom if required, no indication of an adcom has been provided to date.
• The DEA rescheduling process is still expected to occur sequentially after FDA approval; while accelerated engagement is underway, there is no confirmed timeline for earlier completion of rescheduling as of the call.
• CPT-3 codes are currently in Category 3 (tracking status) and will require broader post-launch utilization to be upgraded to valued Category 1 codes, leaving near-term reimbursement levels uncertain for providers.
• Final REMS requirements for Comp360 administration have not yet been finalized by the FDA, which could impact clinical implementation and site readiness.
• The exact level of payer reimbursement and prior authorization rules will not be finalized until after full clinical data is available, creating uncertainty around near-term patient access and revenue assumptions.
• Competitive entry from other psilocybin developers could impact market share, though management notes the large unmet need in TRD and PTSD supports space for multiple approved treatments.

Q: Has the FDA indicated whether it will hold an advisory committee for Comp360, and will the company release long-term 52-week data from the COMP005 trial alongside Q3 2024 COMP006 data?

A: Whether to hold an adcom is entirely the FDA's decision, which will only be made after the full NDA dataset is submitted. Compass is already planning for the possibility of an adcom and has no indication one will or will not be held at this time. Management acknowledges the value of releasing long-term COMP005 data for payer and commercial planning, but has not made a final decision on timing or what data will be released, and will resolve that in due course.

Q: Why is the Q3 2024 26-week COMP006 data still a gating factor for NDA completion even after the CNPV award, and what are the remaining steps for CPT code reimbursement?

A: The rolling NDA submission plan was agreed with the FDA before the CNPV award, and the CNPV only accelerates the final review step, not the required evidentiary basis for approval. The 26-week data is needed to finalize Comp360's efficacy and durability profile for approval and commercial use. The CPT-3 codes are currently in Category 3 tracking status, and will require more utilization data post-approval to be assessed for valued Category 1 status by the AMA RUC committee; providers can negotiate direct reimbursement with payers in the interim. Final REMS staffing requirements will be set via FDA discussion, with current guidance expecting requirements similar to Spravato, requiring a licensed provider on site during treatment.

Q: What is the current share of Spravato patients treated at academic medical centers vs. independent interventional psychiatry clinics, and how will this shape Compass's launch strategy?

A: Less than 5% of current Spravato patients are treated at academic medical centers, which typically lack high-volume throughput capacity. The primary launch focus will be on the ~7,500 existing interventional psychiatry clinics already prescribing Spravato, which have existing capacity and infrastructure to treat high volumes of patients. Academic centers will still offer Comp360, but they are not expected to contribute meaningfully to early launch volume.

Q: How does the room utilization and reimbursement economics of Comp360 compare to Spravato for interventional clinics?

A: Spravato requires multiple shorter treatment sessions per patient, which creates unreimbursed downtime between patient turnovers. At full capacity, a single treatment room can generate ~$900 per day for three Spravato patients. Comp360 requires one ~6-hour treatment session, which can be paired with a Spravato patient in the same room on the same day for most clinics, making Comp360 incremental revenue rather than a tradeoff. Even at full capacity, the total room reimbursement for Comp360 meets or exceeds the revenue from three Spravato patients, giving clinics strong economic incentive to offer the treatment.

Q: What is the clinical rationale for the 4-week dosing interval in the PTSD Phase III trial compared to the 3-week interval used in the TRD Phase III trial?

A: The PTSD trial uses the standard, validated CAHPS5 primary endpoint, which requires a 4-week look-back period to measure symptom change. The 4-week dosing interval is a practical requirement aligned with this endpoint, not a clinical difference in the optimal dose timing for PTSD vs. TRD.